Akari Therapeutics Provides Updates On Development Of Nomacopan In Pediatric And Adult HSCT-TMA
Portfolio Pulse from Happy Mohamed
Akari Therapeutics (NASDAQ:AKTX) has announced updates on the development of nomacopan for treating pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The company is on track to begin patient enrollment in a Phase 3 study of nomacopan in pediatric HSCT-TMA by the end of 2023. It also plans to start a Phase 3 double-blind placebo-controlled clinical trial of nomacopan in adult HSCT-TMA in 2024. The FDA has granted Orphan Drug, Fast Track, and Rare Pediatric Disease designations for nomacopan in pediatric HSCT-TMA.
July 13, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akari Therapeutics is advancing with Phase 3 trials of nomacopan for HSCT-TMA. The FDA has granted Orphan Drug, Fast Track, and Rare Pediatric Disease designations for the drug, which could expedite its approval process.
The advancement of nomacopan into Phase 3 trials indicates positive progress in its development. The special designations granted by the FDA could expedite the approval process, potentially leading to an earlier market entry and revenue generation for Akari. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100